Achilles Therapeutics sells technology assets to AstraZeneca for $12M
Written by Emily J. Thompson, Senior Investment Analyst
Commercial License Transfer: Achilles Therapeutics has transferred the commercial license of data and samples from the TRACERx Non-Small Cell Lung Cancer study to AstraZeneca, which will also sponsor Achilles' Material Acquisition Platform.
Financial Agreement: AstraZeneca will pay Achilles Therapeutics a total of $12 million for the assets, which include extensive genetic data and tumor samples from over 800 lung cancer patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
